Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Jalaja Potluri"'
Autor:
Keith Pratz, Catherine Lai, Brian A. Jonas, Courtney Dinardo, Cat N. Bui, Rajesh Kamalakar, Jalaja Potluri, Wei-Han Chang, Rohini Sen, Thomas W Leblanc
Publikováno v:
HemaSphere, Vol 7, p e925140d (2023)
Externí odkaz:
https://doaj.org/article/c2d7a933cbe240418dc2b574c491f41c
Autor:
David Sharon, Paul Jung, Yan Sun, Weiguo Feng, Ziping Yang, Valerie Robinson, Diya Mitra, Wei Liu, Pingping Zheng, Tami Uziel, Lloyd Lam, Mark Minden, Jeremy Ross, Wellington Mendes, Jalaja Potluri, Andrew Wei, Marina Konopleva, Monique Dail, Brenda Chyla, Pk Epling-Burnette
Publikováno v:
HemaSphere, Vol 7, p e7041879 (2023)
Externí odkaz:
https://doaj.org/article/367ff993d461456dabd8a416bda0598b
Autor:
Keith Pratz, Courtney Dinardo, Martha L Arellano, Michael Thirman, Vinod Pullarkat, Pamela S. Becker, B. Douglas Smith, Meng Zhang, Michael E Werner, Jalaja Potluri, Daniel A. Pollyea
Publikováno v:
HemaSphere, Vol 7, p e68978fe (2023)
Externí odkaz:
https://doaj.org/article/9d932cfaecc64a378a4df2ef7714d55c
Autor:
Marina Konopleva, Courtney D. Dinardo, Yan Sun, Sanam Loghavi, Paul Jung, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea
Publikováno v:
HemaSphere, Vol 7, p e160928c (2023)
Externí odkaz:
https://doaj.org/article/feb327d309ba482292b12a9757915013
Autor:
Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-9 (2022)
Abstract Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO
Externí odkaz:
https://doaj.org/article/1528dc8b9be94e9dbe4fb679eb6e3aa0
Autor:
Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven E. Coutre, Michael Choi, Richard R. Furman, Leonard Heffner, Paul M. Barr, Herbert Eradat, Sharanya M. Ford, Lang Zhou, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, John C. Byrd
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a pha
Externí odkaz:
https://doaj.org/article/2eb9743dadf8446b8ea8d2185f71d8bf
Autor:
Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea
Publikováno v:
Blood. 140:1441-1444
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ebe2cbb454c4b64823569b44defe6d8
https://doi.org/10.1182/blood-2022-169509
https://doi.org/10.1182/blood-2022-169509
Autor:
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero
Publikováno v:
American Journal of Hematology. 98:272-281
Patients with relapsed/refractory (R/R) higher-risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca66a377f5947c1895147bc041ed4ab1
https://doi.org/10.1002/ajh.26771
https://doi.org/10.1002/ajh.26771
Autor:
Anthony Letai, Hagop Kantarjian, Richard Stone, Mack Mabry, Rod Humerickhouse, Joel Leverson, Nancy Falotico, Rachel Kirby, Martin Dunbar, Tapan Kadia, Courtney D. DiNardo, William Blum, Justin L. Ricker, Ming Zhu, Ahmed Hamed Salem, Evelyn McKeegan, Todd Busman, Leah Hogdal, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Marina Konopleva
Supplementary Table S1. Overall activity and predictors of treatment failure (PD or less than partial response by IWG criteria). Supplementary Figure S1. BCL-2 family protein index at screening. Supplementary Figure S2. Mean (+ SD) venetoclax plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b70319b0e96b9e1f3ccc6e1c928c308
https://doi.org/10.1158/2159-8290.22531059.v1
https://doi.org/10.1158/2159-8290.22531059.v1
Autor:
Courtney D. DiNardo, Brenda Chyla, Jalaja Potluri, Yan Sun, Monique Dail, Andre C. Schuh, Sunil Babu, Christian Recher, Brian A. Jonas, Vinod Pullarkat, Andrew H. Wei, Keith W. Pratz, Daniel A. Pollyea
Supplementary Table from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b896ac5aad0d8e9771e4a4a92901640
https://doi.org/10.1158/1078-0432.22488521.v1
https://doi.org/10.1158/1078-0432.22488521.v1